Pfizer Inc. (NYSE:PFE) belongs to Healthcare sector. Its net profit margin is 23.40% and weekly performance is 4.72%. On last trading day company shares ended up $34.82. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is 2.32%. On 9 July, Pfizer Inc (NYSE:PFE) announced enrollment of the first patient in a phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.
Merck & Co. Inc. (NYSE:MRK) shares moved down -0.14% in last trading session and ended the day at $57.87. MRK Gross Margin is 61.40% and its return on assets is 11.00%. Merck & Co. Inc. (NYSE:MRK) quarterly performance is 2.79%. Merck & Co. Inc. (NYSE:MRK) will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter.
On 13 July, Johnson & Johnson (NYSE:JNJ) shares moved up 0.74% and was closed at $100.27. JNJ EPS growth in last 5 year was 5.30%. Johnson & Johnson (NYSE:JNJ) year to date (YTD) performance is -2.74%. Zacks lowered shares of Johnson & Johnson (NYSE:JNJ) from a buy rating to a hold rating in a research report released on Monday morning, AnalystRatingsNetwork.com reports.
Baxter International Inc. (NYSE:BAX) ended the last trading day at $37.60. Company weekly volatility is calculated as 2.11% and price to cash ratio as 8.09. Baxter International Inc. (NYSE:BAX) showed a weekly performance of -1.16%. Baxter International (NYSE:BAX) will host a quarterly conference call to discuss its second quarter 2015 financial results on Wednesday, July 29, 2015, at 4:00 p.m. Central Time.
Eli Lilly and Company (NYSE:LLY) shares moved up 0.60% in last trading session and ended the day at $88.82. LLY Gross Margin is 75.00% and its return on assets is 6.20%. Eli Lilly and Company (NYSE:LLY) quarterly performance is 21.65%. On 10 July, Eli Lilly and Company (NYSE:LLY) provided an update on the recent meeting of the FDA’s Oncologic Drugs Advisory Committee (ODAC) where the company’s regulatory application for necitumumab in combination with gemcitabine and cisplatin was discussed. Lilly is looking to get necitumumab approved for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).